The Food and Drug Administration approved tavapadon, to be marketed as JUVMO, on September 28, 2026, making it the first and only selective D1/D5 dopamine receptor agonist cleared for adults with Parkinson's disease, AbbVie said in its own announcement that day. The once-daily oral tablet is approved for use with or without levodopa, and the company said it expects the drug on U.S. pharmacy shelves in October 2026. The clearance was corroborated the same day by Medscape, Healio, Pharmacy Times and NeurologyLive, all of which described it as the first Parkinson's drug in a genuinely new mechanistic class.

Older dopamine agonists used in Parkinson's disease act mainly on D2 and D3 receptors; tavapadon instead targets the D1 and D5 subtypes. The approval rests on the Phase 3 TEMPO program: three placebo-controlled, 27-week trials in a combined 1,340 adults aged 40 to 80. TEMPO-1 (529 people) and TEMPO-2 (304 people) tested tavapadon alone in early Parkinson's disease; TEMPO-3 (507 people) tested it added to a stable dose of levodopa in people already having motor fluctuations. In TEMPO-1, scores for daily-living activities on the MDS-UPDRS Part II scale improved 1.6 to 1.7 points more than placebo at week 26 (p<0.0001 for each dose), according to AbbVie's release. In TEMPO-3, participants who averaged 5.5 hours of daily 'off' time at baseline gained 1.7 more hours of 'on' time without troublesome dyskinesia on tavapadon, against 0.6 hours on placebo (p<0.0001).

Dosing starts at 0.25 milligrams and is raised over roughly six weeks to a 5 milligram maintenance dose, with further increases allowed to a maximum of 15 milligrams. The label identifies tavapadon as a substrate of the liver enzyme CYP3A, and Pharmacy Times reported that one strong CYP3A inhibitor raised drug exposure fivefold in study data cited in the prescribing information. Tavapadon entered AbbVie's pipeline through its 8.7 billion dollar acquisition of Cerevel Therapeutics, Endpoints News reported the day of approval.